The drug for the treatment of prostate cancer Rakurs (223Ra), developed by specialists of the Federal Medical and Biological Agency, is registered in Russia
The drug destroys bone metastases, enabling a person diagnosed with prostate cancer to prolong their life against the background of the disease, the agency explained. In addition, it affects the…

